| European Case Law Identifier: | ECLI:EP:BA:2015:T222310.20150319 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 19 March 2015 | ||||||||
| Case number: | T 2223/10 | ||||||||
| Application number: | 02755765.1 | ||||||||
| IPC class: | C07K 16/18 C12N 5/16 C12N 15/13 C12N 15/85 C12P 21/08 A61K 39/395 |
||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | D | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | Antibody recognizing GM1 ganglioside-bound amyloid beta-protein and DNA encoding the antibody | ||||||||
| Applicant name: | Medical & Biological Laboratories Co., Ltd. Japan as represented by The Director of Chubu National Hospital Yanagisawa, Katsuhiko |
||||||||
| Opponent name: | Glaxo Group Limited | ||||||||
| Board: | 3.3.04 | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: |
|
||||||||
| Keywords: | Admissibility of appeal - (yes) Late-filed evidence - admitted (yes) Novelty - (yes) Sufficiency of disclosure - (yes) Inventive step - (yes) |
||||||||
| Catchwords: |
- |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t102223eu1.html
Date retrieved: 17 May 2021